BLOOD PRODUCTS ADVISORY COMMITTEE

First Page		Document Content
Blood products HIV/AIDS Hematology Transfusion medicine Plasmapheresis Plasma frozen within 24 hours after phlebotomy HIV test HIV Thrombotic thrombocytopenic purpura Anatomy Blood Medicine		BLOOD PRODUCTS ADVISORY COMMITTEE Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 24,08 KB Share Document on Facebook

	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura Marie Scully, Spero Cataland, Flora Peyvandi, Paul Coppo, DocID: 1utac - View Document
	IP Internship project 7: Detailed characterisation of the molecular interaction between complement factor H (FH) and von Willebrand factor (VWF) Description Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic DocID: 1pS8s - View Document
	Journal of Clinical Apheresis 28:145–Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth DocID: 1pqG9 - View Document
	Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products Address for correspondence: BCSH Secretary British Society for Haematology DocID: 176UN - View Document
	Journal of the Hong Kong Geriatrics Society • Vol. 10 No.2 JulyAN ELDERLY GENTLEMAN WITH SUSPECTED RECURRENT STROKE AND TICLOPIDINE INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA YW Shum. MBBS (HK), MRCP (UK), FHKA DocID: 14YuY - View Document